Vancomycin-resistant Enterococcus faecium: A current perspective on resilience, adaptation, and the urgent need for novel strategies Original paper
Researched by:
-
Divine Aleru
ID
Divine Aleru
Read MoreI am a biochemist with a deep curiosity for the human microbiome and how it shapes human health, and I enjoy making microbiome science more accessible through research and writing. With 2 years experience in microbiome research, I have curated microbiome studies, analyzed microbial signatures, and now focus on interventions as a Microbiome Signatures and Interventions Research Coordinator.
-
Microbes
Microbes
Microbes are microscopic organisms living in and on the human body, shaping health through digestion, vitamin production, and immune protection. When microbial balance is disrupted, disease can occur. This guide explains key microbe types—bacteria, viruses, fungi, protozoa, and archaea—plus major pathogenic and beneficial examples.
-
Divine Aleru
Read More
Researched by:
-
Divine Aleru
ID
Divine Aleru
Read More
Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.
Divine Aleru
What was reviewed?
This review explored the growing threat of Enterococcus faecium (VREfm) in healthcare settings, focusing on its resilience, adaptation, and mechanisms of vancomycin resistance. The authors discussed the molecular evolution of VREfm through the acquisition of resistance genes, especially vanA and vanB, and highlighted the role of mobile genetic elements in their spread. The review also examined the epidemiology, transmission routes, and adaptation strategies that enable VREfm to persist in hospital environments and in the community.
Who was reviewed?
The review evaluated various strains of Enterococcus faecium from clinical and community settings, including hospital-acquired strains resistant to vancomycin. It highlighted the dominance of specific clonal lineages, particularly ST78, in hospital settings, and discussed the growing prevalence of VREfm worldwide. The review also included insights into the genetic and virulence profiles of these strains, focusing on the acquisition of resistance genes through plasmids and horizontal gene transfer.
What were the most important findings?
The review found that VREfm has evolved significantly, becoming one of the most resilient pathogens due to its genetic adaptability. The rise of specific clonal lineages, like ST78, has been associated with increased resistance to vancomycin and other antibiotics. These strains are equipped with various adaptive traits, including mobile genetic elements (plasmids) that carry virulence factors and resistance genes. Additionally, the presence of VREfm is not only a hospital problem but is also spreading through the community, food chain, and livestock, indicating complex transmission routes. Despite the growing prevalence, there are gaps in understanding the full molecular mechanisms driving VREfm’s adaptation, highlighting the urgent need for new strategies to combat these resistant strains.
What are the greatest implications of this review?
This review underscores the need for urgent action to address the growing VREfm threat. With its ability to acquire resistance genes and adapt to various environments, VREfm poses a significant challenge to healthcare systems globally. The study emphasizes the importance of comprehensive surveillance, improved diagnostics, and the development of new therapeutic approaches, including alternative antibiotics and strategies to restore microbiome balance, to effectively combat VREfm and prevent further resistance spread.
Enterococcus faecalis
Enterococcus faecalis is a gut‑adapted, Gram‑positive, non‑spore‑forming facultative anaerobe that becomes an important opportunistic pathogen in healthcare when host barriers are breached or antibiotics select for enterococcal overgrowth. Its clinical impact is driven more by persistence, adhesion, and biofilm biology, quorum‑regulated secreted effectors (fsr‑controlled gelatinase GelE), and high genome plasticity than by a broad repertoire of classical tissue‑destroying toxins. Antimicrobial decision‑making must account for the intrinsic poor activity of cephalosporins, the potential for transferable glycopeptide resistance mediated by van gene clusters, and the need for regimen selection in endocarditis that respects synergy/tolerance and local high‑level aminoglycoside resistance patterns.